



NDA 21-598/S-001
NDA 21-598/S-005

Alcon, Inc.
c/o Alcon Research, Ltd.
Attention: Angela C. Kothe, O.D., Ph.D.
Associate Director, Regulatory Affairs
6201 South Freeway
Fort Worth, Texas 76134-2099

Dear Dr. Kothe:

Please refer to your supplemental new drug applications dated June 4, 2003, received June 5, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Vigamox (moxifloxacin HCl ophthalmic solution) 0.5%.

We acknowledge receipt of your submission dated September 24, 2003.

These supplemental new drug applications provide for the addition of a 1 mL physician sample and revised labeling.

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed immediate carton and container labeling submitted June 4, 2003.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 21-598/S-001, S-005." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

NDA 21-598/S-001

NDA 21-598/S-005

Page 2

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Michael Puglisi, Project Manager, at (301) 827-2090.

Sincerely,

{See appended electronic signature page}

Linda L. Ng, Ph.D.
Chemistry Team Leader for the
Division of Anti-Inflammatory, Analgesic
and Ophthalmic Drug Products, HFD-550
DNDC III, Office of New Drug Chemistry
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Linda Ng
10/3/03 10:06:48 AM